Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 14/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 14/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 14/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 14/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 9/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 7/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21381248 | 0.92 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL24198811 | 0.91 | PDE4A (0.84) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL515570 | 0.91 | PDE4A (0.83) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL21381260 | 0.88 | ADORA2A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL29393229 | 0.85 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL10178116 | 0.85 | PDE4A (0.81) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL21381247 | 0.84 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL516014 | 0.84 | ADORA2B (0.72) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL316171 | 0.83 | PDE4A (0.82) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL22471417 | 0.81 | ADORA2B (0.68) | PDE4APDE4BPDE4CPDE4DADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225481-B2 | Xanthine derivative inhibitors of BET proteins | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-01-18 | — | — | US | disclosed |
| US-20190292186-A1 | XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292186-A1 | XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS | BET1, BRD4, BRD3 | PDE4A 1873/4885PDE4B 1806/4885PDE4C 2442/4885 |
| US-11225481-B2 | Xanthine derivative inhibitors of BET proteins | BET1, BRD4, BRD3 | PDE4A 1873/4885PDE4B 1806/4885PDE4C 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.